BioSpace News Archive

The global digital health market is driven by a rising demand for improved communication between healthcare professionals and patients so as to reduce medication errors and provide improved coordinated care.

Nowadays, improving patient care has become a main concern for all health care providers to achieve a high degree of patient satisfaction due to increasing awareness among people, a rise in demand for better care, and rapidly growing health care regulations.

Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million.

Hansa Biopharma AB will publish its interim report for January-March 2021 at 8:00 CET on April 22, 2021.

Highlight Therapeutics to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data at AACR Virtual Annual Meeting 2021

GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled ‘Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26 tumor-bearing mice’ at the American Association for Cancer Research 2021 Annual Meeting.

Vascular Biogenics Ltd., announced the closing of its underwritten public offering of 6,901,790 ordinary shares, and, to certain investors in lieu thereof, pre-funded warrants to purchase 8,050,000 ordinary shares in an underwritten public offering, at a price to the public of $1.90 per ordinary share and $1.89 per pre-funded warrant.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced publication of the results from the Phase 2b ORCA-1 trial in the scientific journal Nicotine and Tobacco Research.

Expertise within Science Group’s R&D consultancy division is being brought together to form a new consultancy, Sagentia Innovation.

HTL , the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc. , a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership.